Tangled in the web of mass generic consolidation? Let Scrip explain
This article was originally published in Scrip
The drive for consolidation in the generic pharma sector is generating plenty of headlines and hot air. For those feeling a little confused about what exactly is going on with those generic company M&A pursuits, here's a brief summary of the latest.
You may also be interested in...
Valeant Pharmaceuticals International Inc. hired Perrigo Co. PLC's Chairman and Chief Executive Joseph Papa to replace CEO Michael Pearson, but will Papa bridge the gaps between Valeant and its shareholders, debtors and the politicians who are demanding information about the company's drug pricing policies? Or, like Pearson, will he be bitten by the sharks in Valeant's troubled waters?
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.